250. When You Should Worry About LDL Cholesterol with Mike Fave
Paul Saladino MD podcast
00:00
Discussion on PCSK9 Inhibitors and Statins
The chapter analyzes the efficacy and risks of PCSK9 inhibitors like evolocumab and alirocumab, comparing them to statins in terms of cardiovascular benefits and adverse effects. It delves into the mechanism of action of these drugs, their impact on mortality rates, and the challenges in evaluating their risk versus reward due to limited usage and high cost. The conversation also explores the complexities of assessing cardiovascular risk factors beyond just LDL cholesterol levels, emphasizing a comprehensive approach to improve heart health.
Transcript
Play full episode
